BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes

Kessler, Jan H.; Bres-Vloemans, Sandra A.; Veelen, Peter A. van; Ru, Arnoud de; Huijbers, Ivo J.; Camps, Marcel; Mulder, Arend; Offringa, Rienk; Drijfhout, Jan W.; Leeksma, O. C.; Ossendorp, Ferry; Melief, Cornelis J.M.

doi:10.1038/sj.leu.2404354

Cited by 36 publications

(20 citation statements)

References 70 publications

(222 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A low number of predicted epitopes, therefore, is a sign of strength of the prediction phase, provided that these peptides are genuine epitopes. Our experience 69,119 and that of others 126 is that the extended prediction procedure including proteasomal digestion analysis, which selects peptides with high class I binding affinity that are C-terminally liberated by an abundant proteasomal cleavage site, very accurately predicts CTL epitopes. Obviously, selection of peptides according to lower stringent selection criteria may result in the prediction of non-existing class I ligands.…”

Section: Efficiency Of Reverse Immunologymentioning

confidence: 97%

“…In this respect, the lineage-specific differentiation antigens are lower-ranked tumor antigens than purely oncogenic proteins like the HPV16-derived E6 and E7 proteins and the BCR-ABL fusion protein. 69,70 Overexpressed anti-apoptotic proteins like survivin are interesting because downregulation or loss of such TAA would severely inflict the growth potential of the tumor cell. 71,72 Likewise, the telomerase catalytic subunit (hTERT) is involved in the pathogenic process 73 and has a reported anti-apoptotic role.…”

Section: Selection Of Taa For T-cell Immunotherapymentioning

confidence: 99%

“…Proteasomes cleave abundantly at certain sites and cleave much less abundant or do not cleave at other sites. However, due to the broad specificity of the proteasome, the stochastic nature of proteasomal digestion 129,131 (overlapping fragments are often found in the experimental systems 69,119,131 ), and (partly) undefined influences of distant residues on cleavage efficiency, a qualitative and quantitative accurate prediction of proteasomal digestion sites is very complicated. In general, predictions may still result in a high number of improperly predicted cleavage sites.…”

Section: Identification Of T-cell Epitopes For Cancer Immunotherapy Jmentioning

confidence: 99%

“…T cells have mostly been induced in vitro using human PBL from healthy donors. 69,119 Furthermore, PBL 120,151 or TIL 122 from patients with the relevant tumor antigen and restriction element have been used. An alternate approach is the induction of T-cell responses in HLA class I transgenic mice.…”

Section: Validation Phase Of Reverse Immunologymentioning

confidence: 99%

See 3 more Smart Citations

Identification of T-cell epitopes for cancer immunotherapy

2007

Self Cite

View full text Add to dashboard Cite

The effectiveness of T-cell-mediated immunotherapy of cancer depends on both an optimal immunostimulatory context of the therapy and the proper selection with respect to quality and quantity of the targeted tumor-associated antigens (TAA), and, more precisely, the T-cell epitopes contained in these tumor proteins. Our progressing insight in human leukocyte antigen (HLA) class I and class II antigen processing and presentation mechanisms has improved the prediction by reverse immunology of novel cytotoxic T lymphocyte and T-helper cell epitopes within known antigens. Computer algorithms that in silico predict HLA class I and class II binding, proteasome cleavage patterns and transporter associated with antigen processing translocation are now available to expedite epitope identification. The advent of genomics allows a high-throughput screening for tumor-specific transcripts and mutations, with that identifying novel shared and unique TAA. The increasing power of mass spectrometry and proteomics will lead to the direct identification from the tumor cell surface of numerous novel tumor-specific HLA class I and class II presented ligands. Together, the expanded repertoire of tumor-specific T-cell epitopes will enable more precise immunomonitoring and the development of effective epitope-defined adoptive T-cell transfer and multi-epitope-based vaccination strategies targeting epitopes derived from a wider diversity of TAA presented in a broader array of HLA molecules.

show abstract

Section: Efficiency Of Reverse Immunologymentioning

confidence: 97%

Section: Selection Of Taa For T-cell Immunotherapymentioning

confidence: 99%

Section: Identification Of T-cell Epitopes For Cancer Immunotherapy Jmentioning

confidence: 99%

Section: Validation Phase Of Reverse Immunologymentioning

confidence: 99%

See 2 more Smart Citations

Identification of T-cell epitopes for cancer immunotherapy

2007

Self Cite

View full text Add to dashboard Cite

show abstract

“…In general, tumor antigens can be divided into tumor-specific antigens (TSA, e.g. point mutated cellular genes, onco-fusion proteins, or clone-specific idiotypes) [16][17][18][19][20][21][22] and tumor-associated antigens (TAA). In contrast to TSA that are not present in normal cells, the majority of known tumor antigens are derived from normal cellular genes that are expressed at least under certain conditions in normal cells.…”

Section: Introductionmentioning

confidence: 99%

Lipases and Related Molecules in Cancer

Staege

Hesse

Max

2010

Cancer�Growth�Metastasis

View full text Add to dashboard Cite

Lipases are enzymes that catalyze the hydrolysis of lipids. Based on protein structures and sequences, lipases can be classified into different protein families. The majority of conventional mammalian lipases are members of the protein super-families of serine esterases and alpha-beta hydrolases. Differential expression of lipases and related alpha-beta hydrolases in tumor cells has been observed. The physiological or patho-physiological functions of these tumor related enzymes are largely unknown. However, lipases are not only involved in energy metabolism but also in the metabolism of bioactive molecules, e.g. phosphatidic acid or arachidonic acid, suggesting that tumor-specifically expressed lipases might be interesting targets for the development of future treatment strategies. Moreover, independent of the patho-physiological function, tumor associated lipases can serve as targets for immunological treatment strategies. In addition, lipases with exclusive expression in single tumor entities can serve as potential diagnostic targets.

show abstract

T Cell Antigens in Cancer

Paschen

2009

Tumor‐Associated Antigens

View full text Add to dashboard Cite

BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes

Cited by 36 publications

References 70 publications

Identification of T-cell epitopes for cancer immunotherapy

Identification of T-cell epitopes for cancer immunotherapy

Lipases and Related Molecules in Cancer

T Cell Antigens in Cancer

Contact Info

Product

Resources

About